Seasonal Influenza Vaccine Market Size -DPI Research

NEW DELHI - Nov. 23, 2016 - PRLog -- Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.


Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor's part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the

regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.United States

2.United Kingdom

3.France

4.Italy

5.Spain

6.Germany

7.Japan

Major and Promising Vaccines covered in the report are as follows:

1.Fluzone High–Dose

2.Fluzone Quadrivalent

3.Intradermal (ID) Trivalent

4.Vaxigrip

5.Fluarix Quadrivalent

6.Flulaval Quadrivalent

7.Fluenz Tetra

8.FluMist Quadrivalent

9.Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

For more details vist : http://www.dpiresearch.com/index.php
Contact Info:

Name: Sajid Jamal,Relationship Manager

Email: sales@dpiresearch.com

Organization: DPI Research

Phone: + 91 728-994-9987